Dosage forms comprising a plasma kallikrein inhibitor

A method of preparing an oral solid dosage form comprising a compound of Formula A

• wherein the method comprises method (i), method (ii), or method (iii), method (i) comprising the steps of:
• (a) mixing a solid form of the compound of Formula A which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 11.2, 12.5, 13.2, 14.5 and 16.3 with a granulation fluid comprising a binder optionally further comprising water, and optionally a diluent, a disintegrant, and/or a surfactant;
• (b) granulating the dispersion of step (a) to form granules;
• (c) drying the granules;
• (d) optionally blending the granules of step (b) or (c) with a diluent, an acid, a surfactant, and/or a lubricant to form blended granules;
• and
• (e) compressing or filling the granules or blended granules into a solid oral dosage form;
• or
• method (ii) comprising the steps of:
• (a) dispersing a solid form of the compound of Formula A which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 11.2, 12.5, 13.2, 14.5 and 16.3 in molten lipid excipient;
• (b) loading the molten dispersion into a capsule;
• or
• method (iii) comprising loading a capsule with a solid form of the compound of Formula A which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 11.2, 12.5, 13.2, 14.5 and 16.3.